Clinical Trial Update: Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neoadjuvant/adjuvant therapy with sintilimab (PD-1 inhibitor) plus nab-paclitaxel and gemcitabine for resectable or borderline…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Abraxane (nab-paclitaxel) (nab-paclitaxel)
• Gemzar (gemcitabine) (gemcitabine)
• Tyvyt (Sintilimab) (Sintilimab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA | Phase 2 | Status: NOT_YET_RECRUITING